Brief: Achilles Therapeutics Enrolls First U.S. Patient In Ongoing Phase I/IIa Study In Advanced Non-Small Cell Lung Cancer
01/07/2021 13:15
July 1 (Reuters) - Achilles Therapeutics PLC 698y.F :
* ACHILLES THERAPEUTICS ENROLLS FIRST US PATIENT IN ONGOING
PHASE
I/IIA STUDY IN ADVANCED NON-SMALL CELL LUNG CANCER
Source text for Eikon: ID:nGNX5D4wGh
Further company coverage: 698y.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Achilles Therapeutics
See all newsBrief: Achilles Therapeutics Announces Sale Of Technology Assets To Astrazeneca
Brief: Achilles Therapeutics Receives Approval To Transfer To Nasdaq Capital Market
Achilles gains on plans to explore strategic options
Brief: Achilles Therapeutics To Discontinue Development Of TIL-Based cNET Therapy
Brief: Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement